AstraZeneca’s (AZN) “Buy” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research note released on Monday, MarketBeat reports. They currently have a £175 price target on the biopharmaceutical company’s stock.

AZN has been the subject of a number of other research reports. Citigroup lifted their price objective on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Berenberg Bank reiterated a “buy” rating and set a £160 target price on shares of AstraZeneca in a research report on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a £115 price target on shares of AstraZeneca in a research note on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of £152.17.

AstraZeneca Trading Up 2.5%

Shares of AstraZeneca stock opened at £120.36 on Monday. AstraZeneca has a fifty-two week low of £107.84 and a fifty-two week high of £157.32. The firm has a market cap of £186.66 billion, a PE ratio of 18.02, a P/E/G ratio of 0.86 and a beta of 0.23. The business’s fifty day moving average is £132.72 and its two-hundred day moving average is £139.74. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.